文献速递肝胆胰外科胃肠外科

结直肠癌肝转移切除:肿瘤负荷与KRAS突变状态的预后影响

Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
PubMed 文献 · J Am Coll Surg · 2020-12-28

基于国际多中心数据库2001-2018年1361例肝切除患者,评估肿瘤负荷评分(TBS)与KRAS状态对总生存的影响。全队列中TBS和KRAS均与预后相关;但在mutKRAS患者中TBS不能区分长期预后,而wtKRAS患者中TBS与OS强相关。

要点

  • 全队列中低TBS与高TBS的5年OS分别为49.4%和36.7%。
  • wtKRAS患者中低TBS与高TBS的5年OS分别为59.1%和38.4%。
  • mutKRAS患者中TBS不能区分预后,多因素分析非独立预测因子。

核心结论

  • TBS与wtKRAS结直肠癌肝转移患者生存相关,但在mutKRAS患者中肿瘤形态学不能预测长期结局。

研究设计与样本

  • 国际多中心数据库回顾性队列,纳入2001-2018年接受肝切除的结直肠癌肝转移患者1361例。

主要发现

  • 全队列中位转移灶数目2个(IQR 1-3),最大转移灶中位大小3.0 cm(IQR 2.0-5.0 cm),中位TBS 4.1(IQR 2.8-6.1)。
  • KRAS状态分布:wtKRAS 420例(30.9%),mutKRAS 251例(18.4%),未知690例(50.7%)。
  • 全队列中位OS 49.5个月(95%CI 45.2-53.8),5年OS 43.2%。
  • 全队列中TBS与长期预后相关(5年OS低TBS 49.4% vs 高TBS 36.7%),KRAS状态亦相关(wtKRAS 48.2% vs mutKRAS 31.1% vs 未知44.0%),均p<0.01。
  • wtKRAS患者中TBS与OS强相关(5年OS低TBS 59.1% vs 高TBS 38.4%,p=0.002);mutKRAS患者中TBS不能区分预后(5年OS低TBS 37.4% vs 高TBS 26.7%,p=0.19)。

关键数值与推荐

  • 高TBS/wtKRAS与低TBS/mutKRAS患者5年OS相当(38.4% vs 37.4%,p=0.59)。
  • 多因素分析中wtKRAS患者TBS与OS相关(HR 1.43,95%CI 1.02-2.00;p=0.03)。
  • 多因素分析中mutKRAS患者TBS非独立生存预测因子(HR 1.36,95%CI 0.92-1.99;p=0.12)。

临床怎么用

  • 对wtKRAS结直肠癌肝转移患者,可用TBS评估预后并指导术后随访强度。
  • 对mutKRAS患者,TBS的预后区分能力有限,需结合其他因素综合判断。

局限性

  • KRAS状态未知者占50.7%,可能影响KRAS相关分析的代表性。
  • 回顾性多中心数据库设计,存在选择偏倚和信息偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic impact of colorectal liver metastasis (CRLM) morphologic characteristics relative to KRAS mutational status after hepatic resection remains ill defined. STUDY DESIGN: Patients undergoing hepatectomy for CRLM between 2001 and 2018 were identified using an international multi-institutional database. Tumor burden score (TBS) was defined as distance from origin on a Cartesian plane that incorporated maximum tumor size (x-axis) and number of lesions (y-axis). Impact of TBS on overall survival (OS) relative to KRAS status (wild type [wtKRAS] vs mutated [mutKRAS]) was assessed. RESULTS: Among 1,361 patients, the median number of metastatic lesions was 2 (interquartile range [IQR] 1-3), and median size of the largest metastatic lesion was 3.0 cm (IQR 2.0-5.0 cm), resulting in a median TBS of 4.1 (IQR 2.8-6.1); KRAS status was wtKRAS (n = 420, 30.9%), mutKRAS (n = 251, 18.4%), and unknown (n = 690, 50.7%). Overall median and 5-year OS were 49.5 months (95%CI 45.2-53.8) and 43.2%, respectively. In examining the entire cohort, TBS was associated with long-term prognosis (5-year OS, low TBS: 49.4% vs high TBS: 36.7%), as was KRAS mutational status (5-year OS, wtKRAS: 48.2% vs mutKRAS: 31.1%; unknown KRAS: 44.0%)(both p < 0.01). Among patients with wtKRAS tumors, TBS was strongly associated with improved OS (5-year OS, low TBS: 59.1% vs high TBS: 38.4%, p = 0.002); however, TBS failed to discriminate long-term prognosis among patients with mutKRAS tumors (5-year OS, low TBS: 37.4% vs high TBS: 26.7%, p = 0.19). In fact, patients with high TBS/wtKRAS CRLM had comparable outcomes to patients with low TBS/mutKRAS tumors (5-year OS, 38.4% vs 37.4%, respectively; p = 0.59). On multivariable analysis, while TBS was associated with OS among patients with wtKRAS CRLM (hazard ratio 1.43, 95%CI 1.02-2.00; p = 0.03), TBS was not an independent predictor of survival among patients with mutKRAS CRLM (HR 1.36, 95%CI 0.92-1.99; p = 0.12). CONCLUSIONS: While TBS was associated with survival among patients with wtKRAS tumors, CRLM morphology was not predictive of long-term outcomes among patients with mutKRAS CRLM.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Tsilimigras DI, Hyer JM, Bagante F, et al. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status. J Am Coll Surg. 2020. PMID: 33383214. doi:10.1016/j.jamcollsurg.2020.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。